Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-cash Items: 2016-2025

Historic Non-cash Items for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $66.2 million.

  • Collegium Pharmaceutical's Non-cash Items rose 22.31% to $66.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.2 million, marking a year-over-year increase of 22.31%. This contributed to the annual value of $7.0 million for FY2024, which is 47.02% down from last year.
  • Collegium Pharmaceutical's Non-cash Items amounted to $66.2 million in Q3 2025, which was down 13.64% from $76.7 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Non-cash Items ranged from a high of $82.4 million in Q1 2025 and a low of $6.1 million during Q4 2021.
  • In the last 3 years, Collegium Pharmaceutical's Non-cash Items had a median value of $57.3 million in 2023 and averaged $53.9 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first slumped by 53.35% in 2021, then skyrocketed by 67.19% in 2023.
  • Collegium Pharmaceutical's Non-cash Items (Quarterly) stood at $6.1 million in 2021, then skyrocketed by 31.02% to $8.0 million in 2022, then soared by 67.19% to $13.3 million in 2023, then slumped by 47.02% to $7.0 million in 2024, then increased by 22.31% to $66.2 million in 2025.
  • Its last three reported values are $66.2 million in Q3 2025, $76.7 million for Q2 2025, and $82.4 million during Q1 2025.